SEARCH

SEARCH BY CITATION

References

  • Ahn S., Cheng C., Phillips A. G. and Lee C. S. (2004) Reversal of the dopamine transporter in the severely 6-OHDA lesioned striatum with chronic L-DOPA treatment: a Reverse Dialysis study with GBR 12909, in Abstract Viewer/Itinerary Planner, Vol. Online, p Program No. 562.563. Society for Neuroscience, Washington, DC.
  • Alonso-Frech F., Zamarbide I., Alegre M., Rodriguez-Oroz M. C., Guridi J., Manrique M., Valencia M., Artieda J. and Obeso J. A. (2006) Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson’s disease. Brain 129, 17481757.
  • Andersson M., Hilbertson A. and Cenci M. A. (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson’s disease. Neurobiol. Dis. 6, 461474.
  • Arai R., Karasawa N., Geffard M., Nagatsu T. and Nagatsu I. (1994) Immunohistochemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic L-amino acid decarboxylase. Brain Res. 667, 295299.
  • Arai R., Karasawa N., Geffard M. and Nagatsu I. (1995) L-DOPA is converted to dopamine in serotonergic fibers of the striatum of the rat: a double-labeling immunofluorescence study. Neurosci. Lett. 195, 195198.
  • Bergquist F., Shahabi H. N. and Nissbrandt H. (2003) Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod. Brain Res. 973, 8191.
  • Berthet A., Porras G., Doudnikoff E., Stark H., Cador M., Bezard E. and Bloch B. (2009) Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J. Neurosci. 29, 48294835.
  • Bezard E., Brotchie J. M. and Gross C. E. (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat. Rev. Neurosci. 2, 577588.
  • Bianco L. E., Wiesinger J., Earley C. J., Jones B. C. and Beard J. L. (2008) Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats. J. Neurochem. 106, 205215.
  • Blier P., Pineyro G., El Mansari M., Bergeron R. and De Montigny C. (1998) Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann. N Y Acad. Sci. 861, 204216.
  • Carta M., Lindgren H. S., Lundblad M., Stancampiano R., Fadda F. and Cenci M. A. (2006) Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J. Neurochem. 96, 17181727.
  • Carta M., Carlsson T., Kirik D. and Bjorklund A. (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 18191833.
  • Cenci M. A. and Lindgren H. S. (2007) Advances in understanding L-DOPA-induced dyskinesia. Curr. Opin. Neurobiol. 17, 665671.
  • Cenci M. A. and Lundblad M. (2006) Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J. Neurochem. 99, 381392.
  • Cenci M. A. and Lundblad M. (2007) Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson’s disease in rats and mice. Curr. Protoc. Neurosci. Chapter 9, Unit 9, 25.
  • Cenci M. A. and Odin P. (2009) Dopamine replacement therapy in Parkinson′s Disease: past, present and future, in Cortico-Subcortical Dynamics in Parkinson′s Disease (Tseng K.-Y., ed.), pp. 309334. Humana Press, c/o Springer Science+Business Media, New York, NY.
  • Cenci M. A., Lee C. S. and Bjorklund A. (1998) L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 26942706.
  • Chase T. N. (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50, S17S25.
  • Cragg S. J., Nicholson C., Kume-Kick J., Tao L. and Rice M. E. (2001) Dopamine-mediated volume transmission in midbrain is regulated by distinct extracellular geometry and uptake. J. Neurophysiol. 85, 17611771.
  • Dupre K. B., Eskow K. L., Negron G. and Bishop C. (2007) The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res. 1158, 135143.
  • Dupre K. B., Eskow K. L., Steiniger A., Klioueva A., Negron G. E., Lormand L., Park J. Y. and Bishop C. (2008) Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl) 199, 99108.
  • Eskow K. L., Gupta V., Alam S., Park J. Y. and Bishop C. (2007) The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol. Biochem. Behav. 87, 306314.
  • De La Fuente-Fernandez R., Sossi V., Huang Z., Furtado S., Lu J. Q., Calne D. B., Ruth T. J. and Stoessl A. J. (2004) Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson’s disease: implications for dyskinesias. Brain 127, 27472754.
  • Goodwin G. M., De Souza R. J., Wood A. J. and Green A. R. (1986) The enhancement by lithium of the 5-HT1A mediated serotonin syndrome produced by 8-OH-DPAT in the rat: evidence for a post-synaptic mechanism. Psychopharmacology (Berl) 90, 488493.
  • Herve D., Pickel V. M., Joh T. H. and Beaudet A. (1987) Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res. 435, 7183.
  • Jonkers N., Sarre S., Ebinger G. and Michotte Y. (2001) Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat. J. Neural Transm. 108, 559570.
  • Kannari K., Tanaka H., Maeda T., Tomiyama M., Suda T. and Matsunaga M. (2000) Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation. J. Neurochem. 74, 263269.
  • Kannari K., Yamato H., Shen H., Tomiyama M., Suda T. and Matsunaga M. (2001) Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J. Neurochem. 76, 13461353.
  • Kannari K., Shen H., Arai A., Tomiyama M. and Baba M. (2006) Reuptake of L-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters. Neurosci. Lett. 402, 6265.
  • Kitahama K., Geffard M., Araneda S., Arai R., Ogawa K., Nagatsu I. and Pequignot J. M. (2007) Localization of L-DOPA uptake and decarboxylating neuronal structures in the cat brain using dopamine immunohistochemistry. Brain Res. 1167, 5670.
  • Konradi C., Westin J. E., Carta M., Eaton M. E., Kuter K., Dekundy A., Lundblad M. and Cenci M. A. (2004) Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Neurobiol. Dis. 17, 219236.
  • Lee J., Zhu W. M., Stanic D. et al. (2008) Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 131, 15741587.
  • Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N. and Cenci M. A. (2002) Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur. J. Neurosci. 15, 120132.
  • Meissner W., Ravenscroft P., Reese R. et al. (2006) Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol. Dis. 22, 586598.
  • Mela F., Marti M., Dekundy A., Danysz W., Morari M. and Cenci M. A. (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease. J. Neurochem. 101, 483497.
  • Miller D. W. and Abercrombie E. D. (1999) Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J. Neurochem. 72, 15161522.
  • Moukhles H., Bosler O., Bolam J. P., Vallee A., Umbriaco D., Geffard M. and Doucet G. (1997) Quantitative and morphometric data indicate precise cellular interactions between serotonin terminals and postsynaptic targets in rat substantia nigra. Neuroscience 76, 11591171.
  • Munoz A., Li Q., Gardoni F. et al. (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 131, 33803394.
  • Obeso J. A., Rodriguez -Oroz M. C., Rodriguez M., DeLong M. R. and Olanow C. W. (2000) Pathophysiology of levodopa-induced dyskinesias in Parkinson’s disease: problems with the current model. Ann. Neurol. 47(4 Suppl 1): S2232.
  • Olanow C. W. (2004) The scientific basis for the current treatment of Parkinson’s disease. Annu. Rev. Med. 55, 4160.
  • Orosz D. and Bennett J. P. (1992) Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the “hemiparkinsonian” rat. Exp. Neurol. 115, 388393.
  • Pavese N., Evans A. H., Tai Y. F., Hotton G., Brooks D. J., Lees A. J. and Piccini P. (2006) Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 67, 16121617.
  • Rajput A. H., Fenton M. E., Di Paolo T., Sitte H., Pifl C. and Hornykiewicz O. (2004) Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. Parkinsonism Relat. Disord. 10, 221226.
  • Rascol O., Payoux P., Ory F., Ferreira J. J., Brefel-Courbon C. and Montastruc J. L. (2003) Limitations of current Parkinson’s disease therapy. Ann. Neurol. 53(Suppl 3), S3S12. discussion S12–S15.
  • Revuelta M., Venero J. L., Machado A. and Cano J. (1999) Serotonin hyperinnervation in the adult rat ventral mesencephalon following unilateral transection of the medial forebrain bundle. Correlation with reactive microglial and astroglial populations. Neuroscience 91, 567577.
  • Rice M. E. and Cragg S. J. (2008) Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res. Rev. 58, 303313.
  • Robertson G. S. and Robertson H. A. (1989) Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. J. Neurosci. 9, 33263331.
  • Rylander D., Recchia A., Mela F., Dekundy A., Danysz W. and Cenci M. A. (2009) Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 330, 227235.
  • Samadi P., Gregoire L., Morissette M., Calon F., Hadj Tahar A., Dridi M., Belanger N., Meltzer L. T., Bedard P. J. and Di Paolo T. (2008) mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol. Aging 29, 10401051.
  • Sarre S., Yuan H., Jonkers N., Van Hemelrijck A., Ebinger G. and Michotte Y. (2004) In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J. Neurochem. 90, 2939.
  • Sossi V., Dinelle K., Topping G. J., Holden J. E., Doudet D., Schulzer M., Ruth T. J., Stoessl A. J. and De La Fuente-Fernandez R. (2009) Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson’s: an in vivo imaging study. J. Neurochem. 109, 8592.
  • Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T. and Matsunaga M. (1999) Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10, 631634.
  • Tel B. C., Zeng B. Y., Cannizzaro C., Pearce R. K., Rose S. and Jenner P. (2002) Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115, 10471058.
  • Tsai M. J. and Lee E. H. (1996) Characterization of L-DOPA transport in cultured rat and mouse astrocytes. J. Neurosci. Res. 43, 490495.
  • Westin J. E., Lindgren H. S., Gardi J., Nyengaard J. R., Brundin P., Mohapel P. and Cenci M. A. (2006) Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. J. Neurosci. 26, 94489461.
  • Westin J. E., Vercammen L., Strome E. M., Konradi C. and Cenci M. A. (2007) Spatio-temporal patterna of Striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 62, 800810.
  • Winkler C., Kirik D., Bjorklund A. and Cenci M. A. (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson’s disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 10, 165186.
  • Yamada J., Sugimoto Y. and Horisaka K. (1988) The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice. Eur. J. Pharmacol. 154, 299304.